Sugi Predict

Sugi Predict / Compounds / SCHEMBL710939

SCHEMBL710939

SCHEMBL710939

CC(C)Cc1ccc(S(=O)(=O)NC(C)(C)C)s1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.36
▸ ALDH1A1 P00352 6/20 0.36
▸ HPGD P15428 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ SMN1; SMN2 Q16637 4/20 0.35
▸ LOX P28300 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ PARG Q86W56 1/20 0.35
▸ FBP1 P09467 1/20 0.34
▸ PRF1 P14222 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11459274 0.82 L3MBTL1 (0.51) L3MBTL1ALDH1A1HPGDMEN1KMT2A
SCHEMBL21962759 0.78 KMT2A (0.38) L3MBTL1ALDH1A1HPGDMEN1KMT2A
SCHEMBL30151961 0.77 ALDH1A1 (0.44) L3MBTL1ALDH1A1HPGDMEN1KMT2A
SCHEMBL708647 0.77 SMN1; SMN2 (0.40) L3MBTL1ALDH1A1HPGDMEN1KMT2A
SCHEMBL956744 0.75 ALDH1A1 (0.41) L3MBTL1ALDH1A1HPGDLOX
SCHEMBL3096712 0.75 CA2 (0.47) ALDH1A1HPGDLOXCA2
SCHEMBL30970233 0.75 ALDH1A1 (0.43) L3MBTL1ALDH1A1HPGDMEN1KMT2A
SCHEMBL11054324 0.73 KMT2A (0.43) L3MBTL1ALDH1A1HPGDMEN1KMT2A
SCHEMBL29047361 0.73 LMNA (0.32) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL26129683 0.73 FBP1 (0.49) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648850-A1 SELECTIVE ANGIOTENSIN II COMPOUNDS Vicore Pharma AB (SE) 2025-11-19 — — EP disclosed
US-20250214978-A1 AT2R AGONIST Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2025-07-03 — — US disclosed
WO-2025044927-A1 THIOPHENE SULFONYL CARBAMATE AS AT2R AGONIST, AND USE THEREOF 武汉人福创新药物研发中心有限公司 2025-03-06 — — WO disclosed
CN-119504722-A Thiophene sulfonyl carbamate serving as AT2R agonist and application thereof 武汉人福创新药物研发中心有限公司 2025-02-25 — — CN disclosed
EP-4506345-A1 AT2R AGONIST Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2025-02-12 — — EP disclosed
WO-2024149712-A1 SELECTIVE ANGIOTENSIN II COMPOUNDS VICORE PHARMA AB (SE) 2024-07-18 — — WO disclosed
CN-117242071-A Selective angiotensin II receptor ligands 维科尔药物公司 2023-12-15 — — CN disclosed
CN-116891464-A AT2R agonist 武汉人福创新药物研发中心有限公司 2023-10-17 — — CN disclosed
WO-2023193733-A1 AT2R AGONIST 武汉人福创新药物研发中心有限公司 2023-10-12 — — WO disclosed
CN-116568682-A Novel compounds for the treatment of angiotensin II related diseases 维科尔药物公司 2023-08-08 — — CN disclosed
US-8067418-B2 Tricyclic angiotensin II agonists VICORE PHARMA AB (SE) 2011-11-29 — — US disclosed
EP-1869024-B1 NEW TRICYCLIC ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2010-11-10 — — EP disclosed
US-7652054-B2 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2010-01-26 — — US disclosed
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists VICORE PHARMA AB 2009-12-31 — — US disclosed
US-20090215847-A1 Tricyclic Angiotensin II Agonists VICORE PHARMA AB (SE) 2009-08-27 — — US disclosed
US-20090069382-A1 Bicyclic Angiotensin II Agonists VICORE PHARMA AB (SE) 2009-03-12 — — US disclosed
US-20090042931-A1 Tricyclic Angiotensin II Agonists VICORE PHARMA AB (SE) 2009-02-12 — — US disclosed
EP-1395566-B1 TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2007-09-12 — — EP disclosed
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2004-08-26 — — US disclosed
US-5444067-A Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety MERCK & CO., INC. (US) 1995-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists AGTR1, AGTR2, NPY2R L3MBTL1 3159/4885ALDH1A1 3595/4885HPGD 3365/4885
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists AGTR2, AGTR1, NPY4R L3MBTL1 3500/4885ALDH1A1 4115/4885HPGD 3447/4885
US-20090069382-A1 Bicyclic Angiotensin II Agonists AGTR2, AGTR1, BDKRB2 L3MBTL1 2167/4885ALDH1A1 3059/4885HPGD 3804/4885
US-20250214978-A1 AT2R AGONIST AGTR1, AGTR2, AVPR2 L3MBTL1 4367/4885ALDH1A1 2365/4885HPGD 1025/4885
US-20090042931-A1 Tricyclic Angiotensin II Agonists AGTR2, AGTR1, NPY4R L3MBTL1 2785/4885ALDH1A1 4470/4885HPGD 3661/4885
US-20090215847-A1 Tricyclic Angiotensin II Agonists AGTR2, AGTR1, NPY2R L3MBTL1 1694/4885ALDH1A1 4153/4885HPGD 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.